Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Baptist Health South Florida
Iambic Therapeutics, Inc
Barbara Ann Karmanos Cancer Institute
Orano Med LLC
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Taiho Oncology, Inc.
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
Columbia University
Thomas Jefferson University
City of Hope Medical Center
Prelude Therapeutics
Second Affiliated Hospital of Guangzhou Medical University
Northwestern University
Mayo Clinic
Nuvation Bio Inc.
Quadriga Biosciences, Inc.
University of Virginia
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University
Emory University
Novartis
Celgene
IGF Oncology, LLC
University of Illinois at Chicago
Duke University
University of Louisville
SWOG Cancer Research Network
Shenzhen Second People's Hospital
University of Southern California
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
University of Arizona
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Indiana University
Angiochem Inc
University of California, San Francisco
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)